KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Short term Debt (2020 - 2025)

AbCellera Biologics' Short term Debt history spans 6 years, with the latest figure at $8.8 million for Q1 2025.

  • For the quarter ending Q1 2025, Short term Debt fell 82.95% year-over-year to $8.8 million, compared with a TTM value of $8.8 million through Mar 2025, down 82.95%, and an annual FY2024 reading of $8.1 million, down 83.98% over the prior year.
  • Short term Debt for Q1 2025 was $8.8 million at AbCellera Biologics, up from $8.1 million in the prior quarter.
  • The five-year high for Short term Debt was $54.9 million in Q2 2023, with the low at $8.1 million in Q4 2024.
  • Average Short term Debt over 5 years is $30.0 million, with a median of $27.5 million recorded in 2022.
  • Year-over-year, Short term Debt surged 195.99% in 2022 and then tumbled 83.98% in 2024.
  • Tracing ABCL's Short term Debt over 5 years: stood at $22.9 million in 2021, then soared by 92.77% to $44.2 million in 2022, then grew by 14.17% to $50.5 million in 2023, then tumbled by 83.98% to $8.1 million in 2024, then increased by 8.46% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Short term Debt are $8.8 million (Q1 2025), $8.1 million (Q4 2024), and $20.2 million (Q3 2024).